We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Fatal gastrointestinal hemorrhage after a single dose of dabigatran.
- Authors
Kernan, Leah; Ito, Satoru; Shirazi, Farshad; Boesen, Keith
- Abstract
Dabigatran (Pradaxa) is a new oral anticoagulant approved by the Food and Drug Administration (FDA), available internationally and indicated as an alternative to warfarin for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Dabigatran does not require laboratory monitoring and its kinetics allow for a more rapid onset of action with a time to peak concentration of 1.25-1.5 h. We are reporting a fatality resulting from gastrointestinal bleeding after the ingestion of a single dose of dabigatran 150 mg.
- Publication
Clinical toxicology (Philadelphia, Pa.), 2012, Vol 50, Issue 7, p571
- ISSN
1556-9519
- Publication type
Journal Article
- DOI
10.3109/15563650.2012.705290